Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Inclusion Criteria: * Adults (≥18 years old) with radiologically proven parenchymal brain metastases from histologically confirmed non-small cell lung cancer; * KPS score of ≥70; * Each patient must sign a study-specific Informed Consent form Exclusion Criteria: * Liver metastases; * Extracranial metastases in two or more organs; * Known leptomeningeal metastases or subarachnoid spread of tumor; * Prior whole brain radiation; * Plan to use radiosurgery or radiation boost after completion of WBRT; * Planned chemotherapy during study treatment (prior and subsequent chemotherapy is allowed); * Prior total resection of a single brain metastasis; * Laboratory values as follows: LDH \> 1.3 x upper limit of normal (ULN); ANC \< 1500 /mm³; Platelets \< 50,000 /mm³; Creatinine \> 2.0 mg/dL; AST or ALT \> 2 x ULN; Total bilirubin \> 2 x ULN; * Women who are pregnant or lactating